Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Entera Bio Ltd (ENTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ENTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 37.39% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.22M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 51599 | Beta 1.63 | 52 Weeks Range 1.41 - 3.35 | Updated Date 03/31/2025 |
52 Weeks Range 1.41 - 3.35 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date 2025-03-06 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7192.86% |
Management Effectiveness
Return on Assets (TTM) -70.61% | Return on Equity (TTM) -144.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 57850385 | Price to Sales(TTM) 658.83 |
Enterprise Value 57850385 | Price to Sales(TTM) 658.83 | ||
Enterprise Value to Revenue 584.35 | Enterprise Value to EBITDA -1.52 | Shares Outstanding 36832200 | Shares Floating 21261399 |
Shares Outstanding 36832200 | Shares Floating 21261399 | ||
Percent Insiders 16.88 | Percent Institutions 24.47 |
Analyst Ratings
Rating 4 | Target Price 10 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Entera Bio Ltd
Company Overview
History and Background
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered large molecule therapeutics for unmet medical needs. Founded in 2010, it has focused on developing its oral delivery technology to administer therapies typically delivered via injection.
Core Business Areas
- Oral Drug Delivery Technology: Entera Bio develops and utilizes a proprietary oral drug delivery technology platform to enable oral administration of large molecules, including peptides and proteins. This platform aims to improve patient convenience, compliance, and potentially therapeutic efficacy.
- Osteoporosis Therapeutic Development: The company's primary focus is on developing oral formulations for the treatment of osteoporosis and related bone disorders. Their lead product candidate is EB613, an oral formulation of recombinant human parathyroid hormone (rhPTH) (1-34), also known as teriparatide, for osteoporosis.
Leadership and Structure
Entera Bio's leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure includes departments for research and development, clinical operations, and corporate management.
Top Products and Market Share
Key Offerings
- EB613 (Oral Teriparatide): EB613 is Entera Bio's lead product candidate, an oral formulation of teriparatide for the treatment of osteoporosis. As it is still in clinical development, there is no current market share. Competitors for injectable teriparatide include Eli Lilly (Forteo), and biosimilars of teriparatide.
Market Dynamics
Industry Overview
The osteoporosis market is substantial and growing, driven by an aging population and increasing awareness of bone health. Injectable teriparatide is an established treatment, but oral alternatives are highly sought after to improve patient compliance and convenience.
Positioning
Entera Bio aims to disrupt the osteoporosis market with an oral teriparatide formulation, offering a potential alternative to injections. Their competitive advantage lies in their oral delivery technology and the potential for improved patient compliance.
Total Addressable Market (TAM)
The global osteoporosis market is estimated to be worth billions of dollars annually. Entera Bio is positioned to capture a significant share of this market if EB613 is successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary oral drug delivery technology
- Potential to improve patient compliance
- Focus on large unmet medical need
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on a single lead product candidate
- Clinical trial risk
- Lack of commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of oral delivery technology to other therapeutic areas
- Positive clinical trial results
- Increasing awareness of osteoporosis prevention and treatment
Threats
- Competition from existing osteoporosis treatments
- Failure of clinical trials
- Regulatory hurdles
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- LLY
- TEVA
- AAOI
Competitive Landscape
Entera Bio faces competition from established pharmaceutical companies with existing osteoporosis treatments. Their advantage lies in the potential for an oral alternative to injections.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of the company's oral delivery technology and clinical programs.
Future Projections: Future growth is dependent on the successful development and commercialization of EB613 and potential expansion to other therapeutic areas. Analyst projections are varied and depend on clinical trial outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials for EB613 and efforts to secure partnerships for further development and commercialization.
Summary
Entera Bio is a clinical-stage biopharmaceutical company with promising oral drug delivery technology. The success of its lead candidate, EB613, will largely determine its future. The company faces significant financial risks and competition, but also has the potential to disrupt the osteoporosis market with a more convenient treatment option. Successfully navigating clinical trials and securing partnerships are crucial for Entera Bio's long-term growth.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
AMGN
Amgen Inc
AMGN
Amgen Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entera Bio Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-28 | CEO & Director Ms. Miranda J. Toledano M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://www.enterabio.com |
Full time employees 18 | Website https://www.enterabio.com | ||
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.